An adjunct to Buprenorphine in the treatment of opioid use disorder to help increase abstinence and decrease stress-related opioid cravings is which medication?

An adjunct to Buprenorphine in the treatment of opioid use disorder to help increase abstinence and decrease stress-related opioid cravings is which medication?

• A. Clonidine
• B. Methadone
• C. Naltrexone
• D. Gabapentin

Answer: (A)

An adjunctive approach to buprenorphine for opioid use disorder is to ease withdrawal symptoms and dampen stress-triggered cravings, helping patients stay abstinent during treatment. Clonidine fits this role because it is an alpha-2 adrenergic agonist that reduces central sympathetic outflow. By lowering activity in the locus coeruleus, it attenuates autonomic withdrawal symptoms—such as racing heart, high blood pressure, sweating, and agitation—and decreases the stress response that can drive relapse. This makes buprenorphine-supported recovery more tolerable during early abstinence and more sustainable overall. Methadone is another opioid agonist used for treatment, but it’s a separate replacement therapy rather than an adjunct to buprenorphine. Naltrexone is an opioid antagonist that would counter buprenorphine’s effects and can precipitate withdrawal if given while buprenorphine is ongoing. Gabapentin has been explored for various symptoms, but it does not provide the reliable, clinically established reduction in cravings or relapse risk that clonidine offers in this context.

An adjunctive approach to buprenorphine for opioid use disorder is to ease withdrawal symptoms and dampen stress-triggered cravings, helping patients stay abstinent during treatment. Clonidine fits this role because it is an alpha-2 adrenergic agonist that reduces central sympathetic outflow. By lowering activity in the locus coeruleus, it attenuates autonomic withdrawal symptoms—such as racing heart, high blood pressure, sweating, and agitation—and decreases the stress response that can drive relapse. This makes buprenorphine-supported recovery more tolerable during early abstinence and more sustainable overall.

Methadone is another opioid agonist used for treatment, but it’s a separate replacement therapy rather than an adjunct to buprenorphine. Naltrexone is an opioid antagonist that would counter buprenorphine’s effects and can precipitate withdrawal if given while buprenorphine is ongoing. Gabapentin has been explored for various symptoms, but it does not provide the reliable, clinically established reduction in cravings or relapse risk that clonidine offers in this context.